Mesa Laboratories (MLAB) Current Deferred Revenue (2013 - 2026)

Mesa Laboratories has disclosed Current Deferred Revenue across 14 years of filings, most recently posting $14.5 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue fell 3.74% year-over-year to $14.5 million; the TTM figure through Jun 2026 stood at $14.5 million (down 3.74% YoY), while the FY2026 annual figure was $14.7 million, down 0.54% from the prior year.
• Current Deferred Revenue came in at $14.5 million for Q2 2026 at Mesa Laboratories, down from $14.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $16.3 million in Q3 2022 to a low of $14.3 million in Q3 2025.
• Average Current Deferred Revenue over 5 years is $15.1 million, with a median of $14.8 million recorded in 2024.
• Year-over-year, Current Deferred Revenue soared 67.55% in 2022 and slipped 10.04% in 2023.
• Over 5 years, Current Deferred Revenue stood at $16.2 million in 2022, then retreated by 9.33% to $14.7 million in 2023, then retreated by 0.05% to $14.7 million in 2024, then declined by 0.96% to $14.6 million in 2025, then retreated by 0.32% to $14.5 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $14.5 million in Q2 2026, $14.7 million in Q1 2026, and $14.6 million in Q4 2025.